# Wits University’s Johnny Mahlangu is part of a global team behind a breakthrough gene therapy for haemophilia A. The development of this treatment marks a major milestone in international gene therapy research. A Phase 1 trial in India showed patients remained bleed-free for over 27 months after having been injected with this modified virus. If approved by the Food and Drug Administration, it could become the second gene therapy for haemophilia A, offering a long-term alternative to lifelong Factor-Eight replacement therapy.
SA researcher part of gene therapy breakthrough for haemophilia A